Drug development and clinical trials for immunotherapy and radiosensitising drugs

Drug development and clinical trials for immunotherapy and radiosensitising drugs


My name’s Kevin Harrington I’m Professor of
Biological Cancer Therapies here at the Institute of Cancer Research and I lead the Targeted
Therapies team within the division of Radiotherapy and Imaging. A major interest in the laboratory is in using new drugs and new biological agents to make radiation better able to kill cancer
cells and critically we’re working very heavily at the moment on allowing the immune system
to see that form of cancer cell death and to allow patients to make immune responses
against their disease. When we engage with industrial partners our focus really is to
work out what are the most appropriate drugs or biological agents that we can take into
our experiments here in the laboratory and then to work in partnership with them to develop
them. Key to this of course is provision of the material but also some research funding
to allow us to accelerate the progress that we can make and to move things as quickly
as possible towards the clinic.

Leave a Reply

Your email address will not be published. Required fields are marked *